For a patient with heart failure with preserved ejection fraction, should sacubitril‑valsartan (Entresto) be preferred over amlodipine, and what are the appropriate dosing and monitoring guidelines?

Sacubitril-Valsartan Should Be Considered Over Amlodipine for HFpEF, But the Evidence Remains Limited

For patients with heart failure with preserved ejection fraction (HFpEF), sacubitril-valsartan has a Class 2b recommendation (may be considered) and shows modest benefits in reducing heart failure hospitalizations, particularly in those with LVEF ≤60%, while amlodipine has no specific role in HFpEF treatment beyond blood pressure control. The 2022 AHA/ACC/HFSA guidelines prioritize SGLT2 inhibitors (Class 2a) as the preferred first-line therapy for HFpEF, with sacubitril-valsartan as a secondary option 1, 2.

Evidence Quality and Guideline Recommendations

The PARAGON-HF trial (n=4,822) comparing sacubitril-valsartan to valsartan in HFpEF patients (LVEF ≥45%) narrowly missed its primary endpoint of cardiovascular death or total HF hospitalizations (rate ratio 0.87,95% CI 0.75-1.01, p=0.06) 2, 3. However, subgroup analyses revealed significant benefit in patients with LVEF below the median of 57% (rate ratio 0.78,95% CI 0.64-0.95) and in women (rate ratio 0.73,95% CI 0.59-0.90) 2.

The 2025 Canadian guidelines consolidated HFpEF and HFmrEF into "HFnrEF" (nonreduced ejection fraction) and recommend a tiered approach: SGLT2 inhibitors first, followed by ARNIs or MRAs as second-tier options 4.

When to Choose Sacubitril-Valsartan

Sacubitril-valsartan is most appropriate for HFpEF patients with:

• LVEF between 45-60% (greatest benefit demonstrated) 2, 5
• Recent HF hospitalization or elevated natriuretic peptides (BNP or NT-proBNP) 2, 6
• Female sex (stronger treatment effect observed) 2
• eGFR >30 mL/min/1.73 m² and potassium <5.0 mEq/L 2
• Systolic blood pressure ≥100 mmHg to minimize hypotension risk 6

A pooled analysis of PARAGON-HF and PARAGLIDE-HF (n=5,262) demonstrated that sacubitril-valsartan reduced total worsening HF events and cardiovascular death (rate ratio 0.86,95% CI 0.75-0.98, p=0.027), with benefits emerging as early as Day 9 after randomization 5.

Amlodipine's Limited Role in HFpEF

Amlodipine, a dihydropyridine calcium channel blocker, has no specific indication for HFpEF treatment beyond hypertension management. The 2016 ESC guidelines explicitly state that diltiazem and verapamil (non-dihydropyridine CCBs) are not recommended in HFrEF due to increased risk of HF worsening (Class III recommendation) 7. While dihydropyridines like amlodipine are safer in HF, they provide no disease-modifying benefit for HFpEF.

The 2022 AHA/ACC/HFSA guidelines emphasize treating hypertension in HFpEF (Class 1 recommendation) but do not prioritize any specific antihypertensive class for HFpEF beyond GDMT agents 1, 2.

Dosing and Titration Protocol

Starting dose: 49/51 mg (sacubitril/valsartan) twice daily 6

Target dose: 97/103 mg twice daily 6

Titration schedule:

• Double the dose after 2-4 weeks if tolerated
• Monitor blood pressure, renal function (creatinine, eGFR), and potassium at baseline, 1-2 weeks after initiation, and after each dose increase
• Accept up to 30% increase in creatinine if it stabilizes 8

Critical washout period: Allow 36 hours between discontinuing an ACE inhibitor and starting sacubitril-valsartan to minimize angioedema risk 6.

Monitoring and Safety Considerations

Key adverse effects to monitor:

• Hypotension (most common, especially in patients with LVEF >60%) 9, 10: Occurs more frequently with sacubitril-valsartan than valsartan (RR 1.44) 11. Patients with higher LVEF (≥60%) experienced substantially higher treatment-related hypotension risk 9.
• Hyperkalemia: Less common with sacubitril-valsartan than valsartan 2
• Angioedema: Rare but serious (RR 2.66 vs. valsartan) 11
• Renal function decline: Sacubitril-valsartan actually reduced worsening renal function compared to valsartan (HR 0.60,95% CI 0.44-0.83) 5

Practical monitoring tips:

• Check blood pressure supine and standing to detect orthostatic hypotension
• If symptomatic hypotension occurs, separate timing of sacubitril-valsartan from other BP-lowering medications
• Reduce diuretic doses before reducing GDMT doses if hypotension develops
• Monitor NT-proBNP levels: Sacubitril-valsartan reduces NT-proBNP by 17-24% compared to valsartan 3

Clinical Decision Algorithm

Step 1: Confirm HFpEF diagnosis (LVEF ≥45%, elevated natriuretic peptides, structural heart disease)

Step 2: Initiate SGLT2 inhibitor (dapagliflozin 10 mg or empagliflozin 10 mg daily) as first-line therapy 1, 4

Step 3: If patient remains symptomatic or has recent HF hospitalization, consider adding sacubitril-valsartan IF:

• LVEF ≤60% (stronger evidence)
• SBP ≥100 mmHg
• eGFR >30 mL/min/1.73 m²
• Potassium <5.0 mEq/L
• Not on ACE inhibitor within past 36 hours

Step 4: Reserve amlodipine for:

• Additional blood pressure control if needed after GDMT optimization
• Patients with contraindications to sacubitril-valsartan
• Comorbid conditions requiring CCB therapy (e.g., coronary vasospasm)

Important Caveats

The benefit-risk ratio for sacubitril-valsartan diminishes at higher LVEF values. Patients with LVEF >60% experienced more hypotension without clear clinical benefit 9. The 2023 ACC Expert Consensus emphasizes that benefits are "most clearly evident in patients with LVEF below normal" 12.

Sacubitril-valsartan did not reduce cardiovascular or all-cause mortality in HFpEF trials 2, 11, unlike its dramatic mortality benefit in HFrEF. The primary benefit is reduction in HF hospitalizations.

Older patients (≥75 years) have higher event rates and more hypotension with sacubitril-valsartan, though treatment benefits are retained 10. Use lower starting doses and monitor more frequently in elderly patients.

The PARAGON-HF trial excluded patients with NYHA Class IV symptoms, so evidence is limited in advanced HFpEF 3.